Rininsland Frauke, Stankewicz Casey, Weatherford Wendy, McBranch Duncan
QTL Biosystems, 2778 Agua Fria Street, Santa Fe, NM 87507, USA.
BMC Biotechnol. 2005 May 31;5:16. doi: 10.1186/1472-6750-5-16.
High-throughput screening is used by the pharmaceutical industry for identifying lead compounds that interact with targets of pharmacological interest. Because of the key role that aberrant regulation of protein phosphorylation plays in diseases such as cancer, diabetes and hypertension, kinases have become one of the main drug targets. With the exception of antibody-based assays, methods to screen for specific kinase activity are generally restricted to the use of small synthetic peptides as substrates. However, the use of natural protein substrates has the advantage that potential inhibitors can be detected that affect enzyme activity by binding to a site other than the catalytic site. We have previously reported a non-radioactive and non-antibody-based fluorescence quench assay for detection of phosphorylation or dephosphorylation using synthetic peptide substrates. The aim of this work is to develop an assay for detection of phosphorylation of chemically unmodified proteins based on this polymer superquenching platform.
Using a modified QTL Lightspeed assay, phosphorylation of native protein was quantified by the interaction of the phosphorylated proteins with metal-ion coordinating groups co-located with fluorescent polymer deposited onto microspheres. The binding of phospho-protein inhibits a dye-labeled "tracer" peptide from associating to the phosphate-binding sites present on the fluorescent microspheres. The resulting inhibition of quench generates a "turn on" assay, in which the signal correlates with the phosphorylation of the substrate. The assay was tested on three different proteins: Myelin Basic Protein (MBP), Histone H1 and Phosphorylated heat- and acid-stable protein (PHAS-1). Phosphorylation of the proteins was detected by Protein Kinase Calpha (PKCalpha) and by the Interleukin -1 Receptor-associated Kinase 4 (IRAK4). Enzyme inhibition yielded IC50 values that were comparable to those obtained using peptide substrates. Statistical parameters that are used in the high-throughput community to determine assay robustness (Z'-value) demonstrate the suitability of this format for high-throughput screening applications for detection of inhibitors of enzyme activity.
The QTL Lightspeed protein detection system provides a simple mix and measure "turn on" assay for the detection of kinase activity using natural protein substrates. The platform is robust and allows for identification of inhibitors of kinase activity.
制药行业利用高通量筛选来识别与具有药理学意义的靶点相互作用的先导化合物。由于蛋白质磷酸化的异常调节在癌症、糖尿病和高血压等疾病中起关键作用,激酶已成为主要的药物靶点之一。除了基于抗体的检测方法外,筛选特定激酶活性的方法通常仅限于使用小的合成肽作为底物。然而,使用天然蛋白质底物具有这样的优势,即可以检测到通过结合催化位点以外的位点来影响酶活性的潜在抑制剂。我们之前报道了一种基于合成肽底物的用于检测磷酸化或去磷酸化的非放射性且非基于抗体的荧光猝灭检测方法。这项工作的目的是基于这种聚合物超猝灭平台开发一种用于检测化学未修饰蛋白质磷酸化的检测方法。
使用改良的QTL Lightspeed检测方法,通过磷酸化蛋白质与与沉积在微球上的荧光聚合物共定位的金属离子配位基团的相互作用来定量天然蛋白质的磷酸化。磷酸化蛋白质的结合抑制了染料标记的“示踪剂”肽与荧光微球上存在的磷酸结合位点的结合。由此产生的猝灭抑制产生了一种“开启”检测方法,其中信号与底物的磷酸化相关。该检测方法在三种不同的蛋白质上进行了测试:髓鞘碱性蛋白(MBP)、组蛋白H1和磷酸化热稳定蛋白(PHAS - 1)。蛋白质的磷酸化通过蛋白激酶Cα(PKCα)和白细胞介素 - 1受体相关激酶4(IRAK4)进行检测。酶抑制产生的IC50值与使用肽底物获得的值相当。高通量领域用于确定检测稳健性的统计参数(Z'值)表明这种形式适用于高通量筛选应用以检测酶活性抑制剂。
QTL Lightspeed蛋白质检测系统提供了一种简单的混合并测量的“开启”检测方法,用于使用天然蛋白质底物检测激酶活性。该平台稳健,可用于识别激酶活性抑制剂。